title: Myogenic hyperuricemia. A common pathophysiologic feature of glycogenosis types III, V, and VII.
abstract: To identify the mechanism of hyperuricemia in glycogen storage diseases (glycogenoses) that affect muscle, we studied the effects of exercise and prolonged rest on purine metabolism in two patients with glycogenosis type III (debrancher deficiency), one patient with type V (muscle phosphorylase deficiency), and one patient with type VII (muscle phosphofructokinase deficiency). All had hyperuricemia except for one patient with glycogenosis type III. Plasma concentrations of ammonia, inosine, and hypoxanthine increased markedly in all the patients after mild leg exercise on a bicycle ergometer. The plasma urate concentrations also increased, but with a delayed response. Urinary excretion of inosine, hypoxanthine, and urate increased greatly after exercise, consistently with the increases in plasma levels. Hypoxanthine and urate concentrations were extremely high in the plasma and urine of the patient with glycogenosis type VII. With bed rest, the plasma hypoxanthine level returned to normal within a few hours, and the plasma urate concentration decreased from 18.6 to 10.6 mg per deciliter (1106 to 630 mumol per liter) within 48 hours. Similarly, the urinary excretion of these purine metabolites was reduced by bed rest. These findings indicate that muscular exertion in patients with glycogenosis types III, V, and VII causes excessive increases in blood ammonia, inosine, and hypoxanthine due to accelerated degradation of muscle purine nucleotides. These purine metabolites subsequently serve as substrates for the synthesis of uric acid, leading to hyperuricemia.
authors.forename: I
authors.initials: I
authors.lastname: Mineo
authors.forename: N
authors.initials: N
authors.lastname: Kono
authors.forename: N
authors.initials: N
authors.lastname: Hara
authors.forename: T
authors.initials: T
authors.lastname: Shimizu
authors.forename: Y
authors.initials: Y
authors.lastname: Yamada
authors.forename: M
authors.initials: M
authors.lastname: Kawachi
authors.forename: H
authors.initials: H
authors.lastname: Kiyokawa
authors.forename: Y L
authors.initials: YL
authors.lastname: Wang
authors.forename: S
authors.initials: S
authors.lastname: Tarui
mesh_terms: D000328:Adult; D000641:Ammonia / Q000378:metabolism; D006008:Glycogen Storage Disease / Q000097:blood*; D006010:Glycogen Storage Disease Type III / Q000097:blood*; D006012:Glycogen Storage Disease Type V / Q000097:blood*; D006014:Glycogen Storage Disease Type VII / Q000097:blood*; D006801:Humans; D019271:Hypoxanthine; D007042:Hypoxanthines / Q000378:metabolism; D007288:Inosine / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D009132:Muscles / Q000378:metabolism*; D005082:Physical Exertion; D012146:Rest; D014527:Uric Acid / Q000097:blood* / Q000378:metabolism
chemical_list: D007042:Hypoxanthines; D014527:Uric Acid; D019271:Hypoxanthine; D007288:Inosine; D000641:Ammonia